AU4816497A - Receptor specific brain natriuretic peptide (bnp) - Google Patents
Receptor specific brain natriuretic peptide (bnp)Info
- Publication number
- AU4816497A AU4816497A AU48164/97A AU4816497A AU4816497A AU 4816497 A AU4816497 A AU 4816497A AU 48164/97 A AU48164/97 A AU 48164/97A AU 4816497 A AU4816497 A AU 4816497A AU 4816497 A AU4816497 A AU 4816497A
- Authority
- AU
- Australia
- Prior art keywords
- bnp
- natriuretic peptide
- brain natriuretic
- receptor specific
- specific brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 title 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 title 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 title 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73188096A | 1996-10-22 | 1996-10-22 | |
| US08731880 | 1996-10-22 | ||
| PCT/US1997/018384 WO1998017690A1 (fr) | 1996-10-22 | 1997-10-09 | Peptide natriuretique cerebral (bnp) specifique pour un recepteur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU4816497A true AU4816497A (en) | 1998-05-15 |
Family
ID=24941306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU48164/97A Abandoned AU4816497A (en) | 1996-10-22 | 1997-10-09 | Receptor specific brain natriuretic peptide (bnp) |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0939770A1 (fr) |
| JP (1) | JP2001503256A (fr) |
| AU (1) | AU4816497A (fr) |
| CA (1) | CA2269656A1 (fr) |
| WO (1) | WO1998017690A1 (fr) |
| ZA (1) | ZA979060B (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| AU2005235635B2 (en) | 2004-04-21 | 2010-11-18 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| AU2011350066A1 (en) | 2010-12-27 | 2013-07-11 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2016007873A1 (fr) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions et méthodes de traitement de la craniosynostose |
| AU2015357551B2 (en) | 2014-12-05 | 2021-02-25 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| CA2973883A1 (fr) | 2015-01-28 | 2016-08-04 | Alexion Pharmaceuticals, Inc. | Methodes de traitement d'un sujet atteint d'une deficience en phosphatase alcaline |
| AU2016308624B2 (en) | 2015-08-17 | 2022-06-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
| WO2017058822A1 (fr) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp) |
| WO2017074466A1 (fr) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de la craniosynostose chez un patient |
| US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| WO2017173413A1 (fr) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Traitement d'une faiblesse musculaire à l'aide de phosphatases alcalines |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| BR112019020506A2 (pt) | 2017-03-31 | 2020-08-04 | Alexion Pharmaceuticals, Inc. | métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| WO2020033867A2 (fr) | 2018-08-10 | 2020-02-13 | Alexion Pharmaceuticals, Inc. | Procédés de traitement de la neurofibromatose de type 1 et d'états apparentés avec une phosphatase alcaline |
| EP4072579A4 (fr) | 2019-12-09 | 2024-05-01 | Alexion Pharmaceuticals, Inc. | Polypeptides de phosphatase alcaline et leurs procédés d'utilisation |
| MX2023009463A (es) | 2021-02-12 | 2023-09-21 | Alexion Pharma Inc | Polipeptidos de fosfatasa alcalina y metodos para su uso. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2194895T3 (es) * | 1993-11-12 | 2003-12-01 | Genentech Inc | Peptidos natriureticas atriales especifico de un receptor. |
-
1997
- 1997-10-09 WO PCT/US1997/018384 patent/WO1998017690A1/fr not_active Application Discontinuation
- 1997-10-09 EP EP97910899A patent/EP0939770A1/fr not_active Withdrawn
- 1997-10-09 JP JP51943698A patent/JP2001503256A/ja not_active Ceased
- 1997-10-09 CA CA002269656A patent/CA2269656A1/fr not_active Abandoned
- 1997-10-09 AU AU48164/97A patent/AU4816497A/en not_active Abandoned
- 1997-10-09 ZA ZA979060A patent/ZA979060B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2269656A1 (fr) | 1998-04-30 |
| JP2001503256A (ja) | 2001-03-13 |
| WO1998017690A1 (fr) | 1998-04-30 |
| EP0939770A1 (fr) | 1999-09-08 |
| ZA979060B (en) | 1999-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4816497A (en) | Receptor specific brain natriuretic peptide (bnp) | |
| KR20010012568A (ko) | 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 | |
| AU6868398A (en) | Mu-opiate receptor peptides | |
| HUP9901455A3 (en) | Somatostatin peptides | |
| AU5850698A (en) | Video sequence recognition | |
| AU9774098A (en) | Lighter actuation system | |
| AU6996898A (en) | Runway reservation system | |
| AU7966098A (en) | Hm74a receptor | |
| AU7576096A (en) | Il-13 receptor polypeptide | |
| GB9827348D0 (en) | Natriuretic peptide | |
| AU7132898A (en) | Edg-1-like receptor | |
| AU6450196A (en) | Hr-1 receptor | |
| AU6692598A (en) | Growth factor receptor binding protein | |
| AU5412996A (en) | Truncated igf-i | |
| AU6596096A (en) | Calcitonin gene-related peptide receptor component factor (houdc44) | |
| AU6175696A (en) | Hr-1 receptor | |
| ZA965538B (en) | Somatostatin peptides. | |
| AU6820898A (en) | Natriuretic peptide derivatives | |
| AU3388597A (en) | Human type ii gonadotropin-releasing hormone receptor | |
| AU7165998A (en) | Neurotrophic factor receptors | |
| AU1688899A (en) | Novel seven-pass transmembrane receptor protein | |
| AU1999999A (en) | Contryphan peptides | |
| AU4753496A (en) | Human g-protein coupled receptor | |
| AUPO938697A0 (en) | Novel receptor | |
| AU4554493A (en) | Interferon receptor binding peptides |